Levetiracetam Injection, Solution, Concentrate
Product Images NDC 51224-013

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 51224-013). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Tagi Pharma, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image 01

This text provides the number of patients and the dosage in two different groups (one with placebo, one with Levetiracetam) for a study evaluating the efficacy of Levetiracetam in seizure treatment. However, there is not enough information to determine the results or conclusions of the study.*

FDA Label Image

Image 02

FDA Label Image

Image 03

The text shows a table with the percentage of patients on a placebo (N=104) and those on Levetiracetam 3,000 mg/day (N=180). The percentages go from 0% to 45%. There is no further information available.*

FDA Label Image

Image 04

The text represents a chart that compares the percentage of patients who were administered either a placebo or Levetiracetam. The percentage values range from 0% to 45% and are in 5% increments. The chart shows that 19.6% of patients who were administered the placebo experienced the desired effect. The number of patients in the placebo group was 97, while the number of patients administered Levetiracetam was 101.*

FDA Label Image

Image 05

The text presents the percentage of patients who took a placebo or Levetiracetam. The placebo group had 51 participants and had a 19.6% result, while the Levetiracetam group had 58 participants with a 43.1% outcome.*

FDA Label Image

Image 06

This text provides percentages of patients for two different groups, Placebo (N=84) and Levetiracetam (N=79). However, there is no context or further information to explain what these percentages represent.*

FDA Label Image

Image 07

This appears to be a description of a medication called TAGI Phama, which contains 500mg of levetiracetam, 8.2mg of sodium acetate, 45mg of sodium chloride, and glacial acetic acid for pH adjustment, with a recommended dose for intravenous use only. Each box contains ten single-dose vials, each of which is 5mL in volume, and must be diluted before administration. It's recommended that unused portions be discarded, and the product should be stored between 15-30°C (59-86°F).*

FDA Label Image

Image 08

FDA Label Image

Levetiracetam

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.